 Home > Active Ingredient News > Antitumor Therapy > NEJM: Pembrolizumab in the treatment of persistent, recurrent or metastatic cervical cancer (KEYNOTE-826 study)

NEJM: Pembrolizumab in the treatment of persistent, recurrent or metastatic cervical cancer (KEYNOTE-826 study)

 Last Update: 2021-09-29
 Source: Internet
 Author: User

Tags

pd l1 ihc

test 200

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Pembrolizumab is effective against programmed death ligand 1 (PD-L1) positive metastatic or unresectable cervical cancer that progressed during chemotherapy
.
We evaluated the relative benefit of adding pembrolizumab to chemotherapy with or without bevacizumab

Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Wholesale Cheap Price Bulk Price Aclarubicin CAS 57576-44-0

CAS No.: 57576-44-0

$1/UNIT FOB

Vandetanib

CAS No.: 443913-73-3

Different Grade

$0.1/KG EXW

Camptothecin CAS 7689-03-4

CAS No.: 7689-03-4

Pharmacy Grade

$38-45/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.